Multisource Surveillance Study of Pregnancy and Infant Outcomes in Ocrelizumab-Exposed Women With Multiple Sclerosis (MELODIC Study)

First published 28/02/2020

Last updated 02/07/2024

EU PAS number:

EUPAS33879

Study

Planned

Download as PDF

Documents

Study protocol

Initial protocol

Prot BA39732 OCREVUS v1_Redacted

English (904.19 KB - PDF)View document

Updated protocol

BA39732-protocol-v4-0-2023-03-10-Redacted

First published: 22/02/2024

English (1.11 MB - PDF)View document

Study results

Study report

Other information